Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001891 · ClinicalTrials.gov registry record · Phase 3
Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle
A Phase 3 study of Heart Diseases and Coronary Disease, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00001891 is a Phase 3 study of Heart Diseases and Coronary Disease that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 200 participants, below the 5,530-participant average among 85 other Heart Diseases trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00001891, a Phase 3 study of Heart Diseases and Coronary Disease, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Coronary artery disease (CAD) can cause poor blood flow and supply to the heart muscle. It can result in irreversible damage to the heart muscle and poor function. Before treating patients with heart disease it is important to know how well the heart is functioning. Echocardiography is a diagnostic test that can measure heart function. If part of the heart muscle is not working properly due to previous damage, echocardiography can provide information about how much improvement can be expected after treatment (surgery or angioplasty). The purpose of this study is to compare the accuracy of myocardial contrast echocardiography (MCE) to dobutamine echocardiography to detect the potential for damaged heart muscle to be treated and function in patients with heart disease. Myocardial contrast echocardiography (MCE) does not use radioactivity. It uses sound waves like standard echocardiography. However, with MCE patients receive an injection of a "contrast agent" directly into the blood stream through a vein. The contrast agent, called Optison, is made of tiny microbubbles smaller than red blood cells. The echocardiogram can detect these microbubbles in the small blood vessels of the heart muscle and allow researchers to find areas of the heart receiving less blood flow than others. Echocardiography with Dobutamine does not use radioactivity. It uses sound waves, like standard echocardiography. During this echocardiogram patients receive doses of a medication called dobutamine that stimulates the heart to beat stronger and faster. Heart muscle that does not beat stronger after dobutamine is probably dead, usually as a result of a previous heart attack.
Conditions Studied
Interventions
- PROCEDURE Myocardial contrast echocardiography
- PROCEDURE Dobutamine echocardiography
Study Locations (1)
Maryland
- National Heart, Lung and Blood Institute (NHLBI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 1999-05 |
| Est. Completion | 2001-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001891
The ClinicalTrials.gov registry entry for NCT00001891 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,530-participant average among 85 other Heart Diseases trials with a reported enrollment target (96% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Diseases appearing as the primary indexed condition, and to 2 interventions - of which Myocardial contrast echocardiography is the first listed.
NCT00001891 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001891 about?
NCT00001891 is a clinical study titled "Myocardial Contrast Echocardiography (MCE) to Check for Living and Working Heart Muscle". Coronary artery disease (CAD) can cause poor blood flow and supply to the heart muscle. It can result in irreversible damage to the heart muscle and poor function. Before treating patients with heart disease it is important to know how well the heart is functioning. Echocardiography is a diagnostic ...
What is the current status of trial NCT00001891?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 1999-05. Estimated completion is 2001-03.
What conditions does trial NCT00001891 study?
This clinical trial studies the following conditions: Heart Diseases, Coronary Disease.
What interventions are being tested in trial NCT00001891?
The interventions under investigation include: Myocardial contrast echocardiography (PROCEDURE), Dobutamine echocardiography (PROCEDURE).
Who is sponsoring clinical trial NCT00001891?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001891 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lumason® Infusion vs. Bolus Administrations
RECRUITING · Phase 3
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RECRUITING · Phase 3
-
Comparison of Hematocrit Levels in Infant Heart Surgery
COMPLETED · Phase 3
-
Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
COMPLETED · Phase 3
-
Occluded Artery Trial (OAT)
COMPLETED · Phase 3
-
IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.